Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 18 Results

Title
Intervention Indication Therapeutic Area Year Actions
Olaparib maintenance therapy for non-gBRCA mutated high-grade serous ovarian cancer after platinum-based chemotherapy Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Non-gBRCA mutated high-grade serous ovarian cancer Female Reproductive Cancer 2022 View  |  Download
Olaparib monotherapy for BRCA-mutated platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2019 View  |  Download
Pembrolizumab addition to chemotherapy, followed by maintenance with olaparib for BRCA non-mutated advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer – First-line Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2020 View  |  Download
Pembrolizumab in combination with olaparib as maintenance therapy for non-small-cell lung cancer following first line treatment Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Pembrolizumab in combination with olaparib for anti-hormone and chemotherapy failure metastatic castration-resistant prostate cancer – third line Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475) Prostate cancer Male Reproductive Cancer 2020 View  |  Download
Pembrolizumab in combination with olaparib for treatment of metastatic squamous non-small cell lung cancer Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer Chemoradiotherapy , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2023 View  |  Download
Pembrolizumab with or without olaparib following pembrolizumab with chemoradiation therapy for previously untreated, advanced, stage III non-small-cell lung cancer Chemoradiotherapy , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications